Investigating a biomarker for lung development in premature infants
Let-7b in BPD
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11072987
This study is looking at how a tiny molecule called let-7b-5p can help us understand and possibly improve lung health in very premature babies who might develop bronchopulmonary dysplasia (BPD).
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11072987 on ClinicalTrials.gov |
What this research studies
This research focuses on bronchopulmonary dysplasia (BPD), a common condition in extremely low birth weight infants. The study aims to explore the role of a specific microRNA, let-7b-5p, which has been identified as a significant biomarker for predicting the development of severe BPD. Researchers will analyze blood and tracheal aspirate samples from infants to track changes in let-7b-5p levels and their correlation with lung disease progression. Additionally, the study will investigate how inhibiting let-7b signaling can improve lung development and reduce the severity of BPD in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are extremely low birth weight infants who are at risk for developing bronchopulmonary dysplasia.
Not a fit: Patients who are not premature or do not have low birth weight may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for predicting and managing bronchopulmonary dysplasia in premature infants.
How similar studies have performed: Previous research has shown promising results in using biomarkers for monitoring lung diseases, suggesting potential success for this approach.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AMBALAVANAN, NAMASIVAYAM — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: AMBALAVANAN, NAMASIVAYAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.